2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Breast Neoplasms
3092
Neoplasms
2436
Carcinoma, Non-Small-Cell Lung
1863
Prostatic Neoplasms
1617
Colorectal Neoplasms
1422
Lung Neoplasms
1292
Multiple Myeloma
927
Neoplasm Metastasis
919
Leukemia, Myeloid, Acute
874
Pancreatic Neoplasms
847
Ovarian Neoplasms
799
Melanoma
783
Carcinoma, Hepatocellular
736
Stomach Neoplasms
639
Brain Neoplasms
635
Recurrence
633
Squamous Cell Carcinoma of Head and Neck
630
Head and Neck Neoplasms
609
Glioblastoma
566
Lymphoma
539
Uterine Cervical Neoplasms
537
Triple Negative Breast Neoplasms
504
Precursor Cell Lymphoblastic Leukemia-Lymphoma
499
Carcinoma, Renal Cell
497
Hematologic Neoplasms
462
Urinary Bladder Neoplasms
459
Endometrial Neoplasms
459
Colonic Neoplasms
441
Lymphoma, Non-Hodgkin
435
Sarcoma
434
Interventions
relatlimab
1
daratumumab
1
cobimetinib
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Microsatellite Unstable Colorectal Cancer
×
1 year
×
Clear all
NCT02060188
2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2
Completed
385 enrolled
17 charts
2 FDA